Free Newsletter
Texas sues J&J's Janssen Pharma
The state of Texas is suing Johnson & Johnson's Janssen Pharmaceuticals, alleging that the drug company used Texas mental health officials as "pitchmen" and carried out other unseemly tactics to get its antipsychotic medication, Risperdal, on Texas's Medicaid preferred provider drug list. In addition, the state is accusing New Jersey-based Janssen of supplying phony advocacy groups and making other attempts to influence positioning of the medication, essentially defrauding the state over the last 10 years. Report
More stories about Drug Marketing Johnson & Johnson Risperdal Medicaid Fraud Janssen Pharmaceuticals Texas
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: